Hillstar Bio

At Hillstar Bio, we are developing the next wave of precision immunotherapies to change how autoimmune diseases are treated. Our expert team is focused on developing therapies that deliver durable results and improve patient outcomes. Unlike traditional treatments that suppress the immune system, our approach aims to reset it, potentially offering more effective benefits over time. Our lead program, specifically targeting TRBV9+ T cells, will initially focus on treating axial spondyloarthritis (AxSpA), an autoimmune condition with a significant unmet need. It has the potential to treat other immune and inflammatory conditions associated with HLA-B27. Learn more here: https://bit.ly/4iYfiBi #autoimmunedisease #invisibleillness  #immunotherapy #precisionmedicine #healthcareinnovation #autoimmuneawareness #biotech #transformingtreatment #ankylosingspondylitis #tcelltreatment #chronicillness #axspa

Today, we launched Hillstar Bio, a groundbreaking precision immunotherapy company on a mission to transform the landscape of autoimmune treatment. Our innovative approach harnesses the power of precision medicine to develop targeted therapies that aim to reset the immune system, offering new hope for patients with autoimmune disorders.   Our approach is also versatile, leveraging tailored discovery techniques for each therapeutic and free from the constraints of traditional drug development platforms. Learn more here: https://bit.ly/4iYfiBi #autoimmunedisease #invisibleillness  #immunotherapy #precisionmedicine #healthcareinnovation #autoimmuneawareness #tcelltreatment #chronicillness 

We are pleased to introduce Hillstar Bio, a pioneering biotechnology company dedicated to transforming the treatment of autoimmune diseases. Today, we launched with a  $67 million Series A financing led by a syndicate of experienced investors and shareholders from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings, LifeArc Ventures, and Hummingbird Bioscience. Developed by a world-class team of experts, Hillstar’s approach targets and depletes pathogenic immune cells while preserving healthy ones. We aim to reset the immune system and provide patients with durable therapeutic responses, potentially reducing the need for long-term immunosuppressive treatments. Learn more about Hillstar Bio here: https://bit.ly/4iYfiBi #hillstarbio #precisionimmunotherapy #precisionimmunology #autoimmunedisease #immunology #trbv9 #invisibleillness #chronicillness #axspa

We are pleased to introduce Hillstar Bio, a pioneering biotechnology company dedicated to transforming the treatment of autoimmune diseases. Today, we launched with a  $67 million Series A financing led by a syndicate of experienced investors and shareholders from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings, LifeArc Ventures, and Hummingbird Bioscience. Developed by a world-class team of experts, Hillstar’s approach targets and depletes pathogenic immune cells while preserving healthy ones. We aim to reset the immune system and provide patients with durable therapeutic responses, potentially reducing the need for long-term immunosuppressive treatments. Learn more about Hillstar Bio here: https://bit.ly/4iYfiBi #hillstarbio #precisionimmunotherapy #precisionimmunology #autoimmunedisease #immunology #trbv9 #invisibleillness #chronicillness #axspa